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Role of topical tretinoin in melanoma and 
dysplastic nevi 
Frank L. Meyskens, Jr., M.D., Libbie Edwards, M.D., and 
Norman S. Levine, M.D. Tucson, AZ 
The retinoids have been investigated extensively as chemopreventive and 
therapeutic agents in a variety of neoplasms. They have been shown to inhibit 
the proliferation of transformed cell lines in vitro and transplanted tumors 
in vivo. In cultured murine melanoma cells, retinoids inhibit proliferation and 
induce differentiation. Human melanoma cell lines have shown a mixed 
response, The clinical experience with retinoids in melanoma has been limited. 
Previously we investigated the activity of topical B-all-O'ans-retinoic a id 
(Retin-A, vitamin A acid, retinoic acid, and tretinoin) against intracutaneous 
metastases from malignant melanoma. We saw complete remission of 
multiple lesions in one individual and regression f several lesions in a second 
patient. This experience l d us to conduct he present pilot trial of topical 
tretinoin in dysplastic nevus syndrome. The latter is a precursor of malignant 
melanoma. We saw regression of some of the treated lesions to benign nevi 
showing minimal or no dysplasia. Thus topical tretinoin appears to possess 
some activity against melanoma nd at least one of its precursor conditions. 
In view of these preliminary results, more extensive trials are warranted 
to better define the role of tretinoin in the chemoprevention f malignant 
melanoma in high-risk lesions. (J AM ACAD DERMATOL 15:822-825, 1986.) 
The effects of the retinoids on dysplastic and 
neoplastic ells have been widely studied in vitro, 
in vivo, and in humans. They can be divided into 
cytotoxic and tumor-suppressive effects. 1-3 The cy- 
totoxic effects cause tumor regression by direct 
killing of malignant cells, in the manner of classic 
antitumor chemotherapy. The tumor-suppressive 
or chemopreventive effects are those that inhibit 
the development ofpreneoplastic cells into the ma- 
lignant phenotype. In the retinoids the tumor-sup- 
pressive effects are independent of the agent trig- 
gering the neoplastic process. 4 
In cultured murine melanoma cells, both of 
these kinds of effects are observed. 2,3,5"7 In vivo, 
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topical tretinoin (retinoic acid and Retin-A) retards 
the growth of transplanted murine melanomas in 
a dose-dependent fashion. 8The drug inhibits the 
proliferation of melanoma cells and promotes their 
development into mature melanocytes. 5 
The response of human melanoma cell to 
Retin-A in vitro has been mixed. 6'9'1~ Some cell 
lines are inhibited but others show no response, 
and growth is even stimulated in some. We have 
seen marked heterogeneity from patient o patient 
in the response to Retin-A of melanoma cells from 
biopsy specimens, using a soft-agar colony-form- 
ing assay.  9 Results ranged from substantial inhi- 
bition of melanoma-colony formation to no effect 
at all. We have also demonstrated retinoid inhi- 
bition of human melanoma ceils in a standard cell 
culture system. 10 
The clinical experience with retinoids in mela- 
noma has been limited. We noted a response in 
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three of 20 patients with metastatic melanoma 
treated systemically with 13-cis-retinoic acid." 
Previously we treated two patients with topical 
tretinoin for intracutaneous metastases of malig- 
nant melanoma. In one of these patients there was 
complete remission of the treated lesions. In the 
other there was a partial response.'2 
The first patient was a 54-year-old man with 21 
intracutaneous metastases to his axillae. He was 
treated With topical 0.05% tretinoin cream under 
Blenderm occlusive tape. Perilesional erythema 
was noted during treatment. After 1 month all the 
lesions had flattened to nonpalpable, blue-purple 
macules of the same diameter as the original 
papules. 
Four of the treated lesions were biopsied and in 
all instances regression had occurred. Biopsy spec- 
imens showed dermal extracellular and intracel- 
lular melanosis with no evidence of tumor cells. 
The patient died 24 months later of visceral dis- 
ease, but no new skin lesions became vident nor 
had the old lesions changed. 
The second patient was a 59-year-old woman 
with widespread intracutaneous metastases over 
the right biceps. Numerous chemotherapies had 
been unable to control her aggressive local disease. 
There was no evidence of  systemic metastatic dis- 
ease and she was treated with topical tretinoin 
cream, 0.05%, under Blenderm occlusive dress- 
ing. Of the 22 lesions we treated, three appeared 
to respond clinically. Biopsy specimens from two 
regressing lesions were taken and no evidence of 
melanoma was noted. These results suggest hat 
topical retinoid may be capable of controlling mel- 
anoma when administered to high local concen- 
trations. Our experience with these two:patients, 
together with tretinoin's demonstrated chemopre- 
ventive activity in Vitro and in vivo, led us to 
conduct he preliminary trial reported here of top- 
ical tretinoin in the dysplastic nevus syndrome. 
TOPICAL RETINOIC ACID THERAPY FOR 
MULTIPLE DYSPLASTIC NEVI 
The dysplastic nevus syndrome is a recently 
characterized ntity '3,14 that produces tan, brown, 
or reddish-brown r acules or fiat papules that on 
histologic examination demonstrate dysplastic me- 
]anocytic hanges in a nevocellular nevus. These 
lesions may number from 1 to greater than 100. 
Their shape is irregular and often large (5 mm). 
They usually appear first at about the time of pu- 
berty, but new dysplastie nevi may develop 
throughout life. Both a familial type ~ and a more 
common sporadic '6 type have been described. 
They have identical histologic features. 
These nevi may often be precursors to mela- 
noma but it has been difficult to predict which 
dysplastic nevi will evolve to malignant tumors. 17 
Therapeutic strategies that might eradicate these 
preneoplastic lesions before malignant ransfor- 
mation could avert significant morbidity and death. 
In patients with only a few lesions, this can be 
accomplished by surgical excision. Surgery is im- 
practical and may be unacceptable to patients with 
many lesions, however. Furthermore, it has no 
value in preventing melanomas that arise de novo 
in previously normal skin. Currently the most com- 
mon approach is to follow the nevi closely with 
serial clinical photographs and excise those show- 
ing melanoma's clinical changes. ~s Although the 
topical application of fluorouracil '9may be an al- 
ternative, responses to its use have been erratic. 
Recognizing that melanocytes from nevi may 
well be regulated differently than melanoma 
cells, we treated multiple dysplastic nevi in three 
patients with topical tretinoin in ah effort o exploit 
the potential cancer-chemopreventive eff cts of 
retinoids. 
Subjects and protocol 
Patient A, a 58-year-old white man, was evaluated 
at the Un{versity of Arizona Health Sciences Center 
after removal of a cutaneous melanoma. He had no 
known family history of melanoma or dysplastic nevi. 
Examination of this patient's kin revealed a poorly 
demarcated 1 cm red plaque with flecks of blue pigment 
on the right shoulder. Distributed over the trunk were 
numerous 0.5 to 1.5 cm irregular, barely palpable, tan- 
red papules. Before beginning our experimental pro- 
tocol, the patient's houlder lesion was excised and 
found to be melanoma in situ. 
Patient B, a 17-year-old white boy, was referred for 
evaluation of abnormal-appearing nevi. His mother had 
a history of cutaneous melanoma. His sister had dysplas- 
tic nevus yndrome. On examination there were found 
numerous, irregular, red-brown macules with uneven 
pigmentation. Most were 0.5 to 1.0 cm in diameter. 
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Patient C was a 46-year-old white man who had 
undergone excision of four cutaneous melanomas dur- 
hag the previous year. His brother had a similar history 
of cutaneous melanoma. The patient displayed numer- 
ous large, poorly marginated macules and papules 
whose color varied from red-brown to faint red. 
Before therapy, each patient had had at least three 
diagnostic skin biopsy specimens representative of dys- 
plastic nevi. Small portions of the lesions were removed 
to confirm the diagnosis histologically. A portion of 
each lesion remained for treatment. After informed con- 
sent was obtained, all three patients were treated with 
a 0.05% solution of tretinoin cream applied aily to 
individual lesions. A number of biopsied lesions, clin- 
ically characteristic of dysplastic nevi, were treated. 
These we covered with Blenderm occlusive tape, which 
remained in place until the next retinoid application. 
Patient A was treated at home daily for 12 weeks. 
At the end of that ime, biopsies of portions of three 
previously biopsied lesions were performed. Four 
months later, and again 3 months after that, additional 
skin specimens were taken from the same lesions. 
Patient B received aily treatment a home for 10 
weeks. This patient's therapy was discontinued 2 weeks 
early when he entered college. Repeat biopsies of three 
treated sites were performed after 113 weeks. 
In our clinic, topical tretinoin was applie d to patient 
C for 5 days each week for 12 weeks. Subtotal biopsies 
were performed on four of the treated nevi. Three 
months and 8 months after treatment, repeat biopsies 
were performed on these lesions. As was true of the 
first two subjects, the only treatment side effects patient 
C had were mild pruritus and erythema at the site of 
treatment. 
Each biopsy specimen was interpreted at the 
University of Arizona Health Sciences Center by 
a staff pathologist and a dermatologist who were 
unaware of the nature of our experiment protocol. 
The following histologic riteria were the basis for 
diagnosis of dysplastic nevi: (1) junctional mela- 
nocytic proliferation i  large nests, with absent o 
minimal cellular atypia; (2) downward prolifera- 
tion and bridging of rete ridges; (3) spread of single 
large melanocytes along the basal layer; and (4) 
dermal ymphocytic and mesenchymal response. 
The concurrent presence of all criteria was not 
required for diagnosis of dysplastic nevus5 ~
RESULTS 
At the end of treatment, some treated lesions 
had lost their red hues and were more uniformly 
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brown, but most of the lesions showed only min- 
imal changes in clinical appearance: Nevertheless, 
striking histologic hanges were noted after treat- 
ment. Pretreatment skin biopsy specimens of clin- 
ically dysplastic nevi from our three patients all 
showed the characteristic histologie features of 
dysplastic nevi. Multiple-step sections through the 
posttherapy biopsies showed benign compound 
nevi without dysplasia in patients A and C, 
whereas all three posttreatment biopsies in patient 
B were interpreted as benign compound nevi with 
minimal dysplastic hange. In patients A arid C, 
skin biopsy specimens were taken from treated 
lesions several months after treatment. All contin- 
ued to show changes of benign nevocellular nevi 
without dysplasia. 
DISCUSSION 
Three patients with multiple dysplastic nevi 
were treated with topical retinoic acid. All lesions 
biopsied after treatment and again several months 
later demonstrated features of either benign com- 
pound nevi with no dysplastie changes or only 
minimal residual dysplasia. 
These preliminary results from a limited study 
are encouraging and call for more extensive trials 
of the use of topical tretinoin to resolve the dys- 
plastic nevus syndrome. An agent effective in this 
role would have considerable value in the che- 
m0prevention of melanoma. Unfortunately, this 
study's design allows for alternative interpreta- 
tions of the results. It may be that the benign ap- 
pearance of the posttreatment biopsy specimens 
was a sampling artifact. Since dysplastic nevi often 
have only focal melanocytic dysplasia, the post- 
treatment biopsy specimens conceivably may have 
represented areas of benign nevus. It is also pos- 
sible that the inflammation caused by the pretreat- 
merit biopsy could have induced resolution of 
the dysplastic hanges independently of retinoid 
therapy. 
In related work, early results from a carefully 
designed trial of systemic 13-cis-retinoic acid sug- 
gest that this retinoid neither suppresses nor re- 
verses dysplastic nevi? 1 
It is important to pursue the study of the reti- 
noids in this and other preneoplastic conditions, 
since this class of drugs may have great potential 
for cancer chemoprevention. The development of
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relevant in v i t ro  screening systems for the evalu- 
ation o f  d rug  effects should be a high priority. 
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